Comparative Pharmacology
Head-to-head clinical analysis: BUTICAPS versus NEMBUTAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTICAPS versus NEMBUTAL SODIUM.
BUTICAPS vs NEMBUTAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
500 mg orally every 8 hours.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
None Documented
None Documented
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
Category C
Category C
Barbiturate
Barbiturate